secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001104659-24-061998
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee starts Phase 2 AD trial for APG777; Phase 1 shows ~75-day half-life
--------------------------------------------------------------------------

- Initiated dosing in Phase 2 trial of APG777 for moderate-to-severe atopic dermatitis (AD).
- Phase 1 healthy volunteer data showed half-life of ~75 days and potentially best-in-class PK profile.
- 16-week proof-of-concept data from Part A expected in 2H 2025; dose optimization Part B also planned.
- APG777 designed for less frequent dosing: 6 injections during induction vs 11 for lebrikizumab, 70-90% fewer in maintenance.
- Phase 2 asthma trial expected to initiate in 2025; pipeline-in-a-product strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000110465924061998/0001104659-24-061998-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000110465924061998/tm2414616d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-061998

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer